Westfield Capital Management Co. LP Has $10.14 Million Stake in BioMarin Pharmaceutical Inc. (BMRN)

Westfield Capital Management Co. LP decreased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 57.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,610 shares of the biotechnology company’s stock after selling 152,395 shares during the period. Westfield Capital Management Co. LP owned 0.06% of BioMarin Pharmaceutical worth $10,136,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BMRN. Parallel Advisors LLC grew its stake in shares of BioMarin Pharmaceutical by 13.6% in the 1st quarter. Parallel Advisors LLC now owns 1,042 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 125 shares during the period. Global X Management Co. LLC grew its stake in shares of BioMarin Pharmaceutical by 59.7% in the 1st quarter. Global X Management Co. LLC now owns 1,656 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 619 shares during the period. Korea Investment CORP grew its stake in shares of BioMarin Pharmaceutical by 143.5% in the 2nd quarter. Korea Investment CORP now owns 1,595 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 940 shares during the period. Mutual of America Capital Management LLC grew its stake in shares of BioMarin Pharmaceutical by 20.0% in the 1st quarter. Mutual of America Capital Management LLC now owns 2,066 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 344 shares during the period. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at approximately $213,000. 97.46% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Westfield Capital Management Co. LP Has $10.14 Million Stake in BioMarin Pharmaceutical Inc. (BMRN)” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://stocknewstimes.com/2017/09/20/westfield-capital-management-co-lp-has-10-14-million-stake-in-biomarin-pharmaceutical-inc-bmrn.html.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 92.10 on Wednesday. The stock’s market capitalization is $16.14 billion. BioMarin Pharmaceutical Inc. has a 12 month low of $78.42 and a 12 month high of $100.51. The firm has a 50 day moving average of $86.72 and a 200-day moving average of $89.48.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. BioMarin Pharmaceutical had a negative net margin of 15.54% and a negative return on equity of 5.77%. The business had revenue of $317.50 million for the quarter, compared to analysts’ expectations of $311.41 million. During the same period in the previous year, the company posted ($2.61) earnings per share. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Analysts forecast that BioMarin Pharmaceutical Inc. will post ($0.71) earnings per share for the current year.

In other news, SVP Brian Mueller sold 2,671 shares of the business’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total transaction of $267,100.00. Following the transaction, the senior vice president now directly owns 15,556 shares of the company’s stock, valued at $1,555,600. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director V Bryan Lawlis sold 3,750 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $91.26, for a total transaction of $342,225.00. Following the transaction, the director now directly owns 19,660 shares in the company, valued at $1,794,171.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 31,265 shares of company stock worth $2,917,755. Corporate insiders own 2.50% of the company’s stock.

Several analysts have recently weighed in on BMRN shares. Sanford C. Bernstein assumed coverage on shares of BioMarin Pharmaceutical in a research note on Thursday, July 27th. They issued a “market perform” rating and a $89.00 price target for the company. Evercore ISI assumed coverage on shares of BioMarin Pharmaceutical in a report on Wednesday, August 16th. They issued an “outperform” rating and a $100.00 price objective on the stock. Royal Bank Of Canada assumed coverage on shares of BioMarin Pharmaceutical in a report on Thursday, September 14th. They issued a “sector perform” rating and a $93.00 price objective on the stock. SunTrust Banks, Inc. restated a “buy” rating and issued a $115.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, July 14th. Finally, Barclays PLC restated an “equal weight” rating and issued a $100.00 price objective (down from $105.00) on shares of BioMarin Pharmaceutical in a report on Saturday, July 22nd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have given a buy rating to the company. BioMarin Pharmaceutical currently has a consensus rating of “Hold” and a consensus target price of $109.09.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply